Voyager Therapeutics (VYGR) EBITDA (2014 - 2026)

Voyager Therapeutics has disclosed EBITDA across 13 years of filings, most recently posting -$26.4 million for Q2 2026.

• In Q2 2026, EBITDA rose 27.94% year-over-year to -$26.4 million; the TTM figure through Jun 2026 stood at -$117.2 million (up 5.03% YoY), while the FY2025 annual figure was -$131.8 million, down 58.3% from the prior year.
• EBITDA came in at -$26.4 million for Q2 2026 at Voyager Therapeutics, up from -$30.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $122.9 million in Q1 2023 to a low of -$38.3 million in Q4 2024.
• Average EBITDA over 5 years is -$11.1 million, with a median of -$25.0 million recorded in 2022.
• Year-over-year, EBITDA sank 530.78% in 2022 and jumped 675.57% in 2023.
• Over 5 years, EBITDA stood at -$24.6 million in 2022, then jumped by 320.1% to $54.1 million in 2023, then plunged by 170.84% to -$38.3 million in 2024, then climbed by 21.85% to -$29.9 million in 2025, then rose by 11.83% to -$26.4 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$26.4 million in Q2 2026, -$30.3 million in Q1 2026, and -$29.9 million in Q4 2025.